ReviewInternational journal of molecular sciences2010
Biomarkers for colorectal cancer.
Review in International journal of molecular sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 234 citations in OpenAlex.
- The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia.Updates in surgery · 2017Trial
- Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis.Pathology oncology research : POR · 2016Trial
- Gut Microbiota and Colorectal Cancer: Is Microbial Dysbiosis in Carcinogenesis an Emerging Risk Factor?Cureus · 2026Review
- Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights.Current cancer drug targets · 2026Review
- Glycoproteomics analysis of colorectal cancer reveals differential alterations of glycoproteins and glycans.Analytical and bioanalytical chemistry · 2025Article
- Utility of Stool-Based Tests for Colorectal Cancer Detection: A Comprehensive Review.Healthcare (Basel, Switzerland) · 2024Review
- Serum IGFBP-1 as a promising diagnostic and prognostic biomarker for colorectal cancer.Scientific reports · 2024Article
- Article
- Recent Advances in Inflammatory Diagnosis with Graphene Quantum Dots Enhanced SERS Detection.Biosensors · 2022Review
- Assessment of the Anti-Cancer Efficiency of Silver Moringa oleifera Leaves Nano-extract against Colon Cancer Induced Chemically in Rats.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- LAMTOR5 expression level is a biomarker for colorectal cancer and lncRNA LAMTOR5-AS1 predicting miRNA sponging effect.Molecular biology reports · 2021Article
- Review
- Abilities of Pre-Treatment Inflammation Ratios as Classification or Prediction Models for Patients with Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Identification of key candidate genes and pathways associated with colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression.Gastroenterology and hepatology from bed to bench · 2021Article
- Evaluation of the Biological Efficiency of Silver Nanoparticles Biosynthesized Using Croton tiglium L. Seeds Extract against Azoxymethane Induced Colon Cancer in Rats.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- RNA-based therapeutics for colorectal cancer: Updates and future directions.Pharmacological research · 2020Review
- Gut Bacteria and their Metabolites: Which One Is the Defendant for Colorectal Cancer?Microorganisms · 2019Review
- Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer.Hormones & cancer · 2019Article
- Identification of potential diagnostic biomarkers for pneumonia caused by adenovirus infection in children by screening serum exosomal microRNAs.Molecular medicine reports · 2019Article
- Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis.Open biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common epithelial malignancy in the world. Since CRC develops slowly from removable precancerous lesions, detection of the lesion at an early stage by regular health examinations can reduce the incidence and mortality of this malignancy. Colonoscopy significantly improves the detection rate of CRC, but the examination is expensive and inconvenient. Therefore, we need novel biomarkers that are non-invasive to enable us to detect CRC quite early. A number of validation studies have been conducted to evaluate genetic, epigenetic or protein markers for identification in the stool and/or serum. Currently, the fecal occult blood test is the most widely used method of screening for CRC. However, advances in genomics and proteomics will lead to the discovery of novel non-invasive biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.